link.springer.com

Therapeutic applications of oncogenes

References

  1. Seeger RC, Brodeur GM, Sather H, et al.: Association of multiple copies of the N-rayc oncogene with rapid progression of neuroblastoma. N Engl J Med 313:1111–1117, 1985.

    Article  PubMed  CAS  Google Scholar 

  2. Brodeur GG, Seeger RC, Schwab M, et al.: Amplification of N-myc in untreated human neuroblastoma correlates with advanced disease stage. Science 224:1121–1124, 1984.

    Article  PubMed  CAS  Google Scholar 

  3. Heisterkamp N, Stephenson JR, Groffen J: Localization of the c-abl oncogene adjacent to a translocation breakpoint in chronic myelocytic leukemia. Nature 306:239–242, 1983.

    Article  PubMed  CAS  Google Scholar 

  4. Bienerhassett GT, Further ME, Anderson A, Burns JP, et al.: Clinical evaluation of a DNA probe for the Philadelphia translocation in chronic myelogenous leukemia. Leukemia 2:648–657, 1988.

    Google Scholar 

  5. Schaefer-Rego K, Dudek H, Popenoe D, et al.: CML patients in blast crisis have breakpoints localized to a specific region of the bcr. Blood 70:448–455, 1987.

    PubMed  CAS  Google Scholar 

  6. Mills KI, MacKenzie ED, Birnie GD: The site of the breakpoint within bcr is a prognostic factor in Philadelphia-positive CML patients. Blood 72:1237–1241, 1988.

    PubMed  CAS  Google Scholar 

  7. Kantarjian HM, Smith TL, McCredie KB, et al.: Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood 66:1326–1335, 1985.

    PubMed  CAS  Google Scholar 

  8. Liu E, Hjelle B, Morgan R, Hecht F, Bishop JM: Mutations of the Kirsten ras proto-oncogene in myelodysplastic syndrome. Nature 330:186–188, 1987.

    Article  PubMed  CAS  Google Scholar 

  9. Hirai H, Kobayashi Y, Mano H, et al.: A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature 327:430–432, 1987.

    Article  PubMed  CAS  Google Scholar 

  10. Appelbaum FR, Storb R, Ramberg RE, et al.: Treatment of preleukemic syndromes with marrow transplantation. Blood 60:92–96, 1987.

    Google Scholar 

  11. Ribeiro RC, Abromowitch M, Raimondi SC, Murphy SB, Behm F, Williams DL: Clinical and biological hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia. Blood 70:948–953, 1987.

    PubMed  CAS  Google Scholar 

  12. Weiss LM, Warnke RA, Sklar J, Cleary M: Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med 317:1185–1189, 1987.

    Article  PubMed  CAS  Google Scholar 

  13. Aisenberg AC, Wilkes BM, Jacobson JO: The bcl-2 gene is rearranged in many diffuse B-cell lymphomas. Blood 71:969–972, 1988.

    PubMed  CAS  Google Scholar 

  14. Varley JM, Walker RA, Casey G, Brammar WJ: A common alteration to the int-2 proto-oncogene in DNA from primary breast carcinomas. Oncogene 3:87–91, 1988.

    CAS  Google Scholar 

  15. Escot, C, Theillet C, Lidereau R, Spyratos F, Champeme M, Gest J, Callahan R: Genetic alteration of the c-myc protooncogene in primary human breast carcinomas. Proc Natl Acad Sci USA 83:4834–4838, 1986.

    Article  PubMed  CAS  Google Scholar 

  16. Slamon DJ, Clark GM, Wong S, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-1/ neu oncogene. Science 235:177–182, 1987.

    Article  PubMed  CAS  Google Scholar 

  17. van der Vijver M, van de Bersselaar R, Devilee P, Cornelisse C, Peterse J, Nusse R: Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol 7:2019–2023, 1987.

    PubMed  Google Scholar 

  18. Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA: Alterations of either c-erbB-2 (neu) or c-myc protooncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1:423–430, 1987.

    PubMed  CAS  Google Scholar 

  19. Lippman ME: Oncogenes and breast cancer. N Engl J Med 319:1281–1282, 1988.

    Article  PubMed  CAS  Google Scholar 

  20. Senn HP, Tran-Thang C, Wodnar-Filipowicz A, Jiricny J, Fopp M, Gratwohl A, Signer E, Weber W, Moroni C: Mutation analysis of the N-ras protooncogene in active and remission phase of human acute leukemias. Int J Cancer 41:59–64, 1988.

    Article  PubMed  CAS  Google Scholar 

  21. Layton DM, Mufti GJ, Lyons J, Janssen JWG, Bartram CR: Loss of ras oncogene mutation in a myelodysplastic syndrome after low dose cytarabine therapy. N Engl J Med 318: 1468–1469, 1988.

    Article  PubMed  CAS  Google Scholar 

  22. Kawasaki ES, Clark SS, Coyne MY, Smith SD, Champlin R, Witte ON, McCormick FP: Diagnosis of chronic myeloid and acute lymphocytic leukmias by detection of leukemia specific mRNA sequences amplification in vitro. Proc Natl Acad Sci USA 85:5698–5702, 1988.

    Article  PubMed  CAS  Google Scholar 

  23. Lee MS, Chang KS, Cabanillas E, et al.: Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science 237:175–178, 1987.

    Article  PubMed  CAS  Google Scholar 

  24. Venturelli D, Lange B, Narni F, Selleri L, Mariano MT, Torelli U, Gewirtz AM, Calabretta B: Prognostic significance of short term effects of chemotherapy on MYC and histone H3 mRNA levels in acute leukemia patients Proc Natl Acad Sci USA 85(10):3590–3594, 1988.

    Article  PubMed  CAS  Google Scholar 

  25. Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI: Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal anti-bodies. Cell 41:695–706, 1988.

    Article  Google Scholar 

  26. Akiyama T, Sudo, Ogawara T, et al.: The product of the human c-erbB-2 gene: 185 kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644–1646, 1986.

    Article  PubMed  CAS  Google Scholar 

  27. Bargman C, Hung MC, Weinberg R: Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of pl85. Cell 45:649–657, 1986.

    Article  Google Scholar 

  28. Semba K, Kamata N, Toyoshima K, Yamamoto T: A v-erbB related protooncogene, c-erbB-2 is distinct from the c-erbB-1 epidermal growth factor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 82:6497–6501, 1985.

    Article  PubMed  CAS  Google Scholar 

  29. Drebin JA, Link VC, Weinberg RA, Greene MI: Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene encoded tumor antigen. Proc Natl Acad Sci USA 83:9129–9133, 1986.

    Article  PubMed  CAS  Google Scholar 

  30. Drebin JA, Link VC, Greene MI: Monoclonal antibodies reactive with distinctive domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene 2:273–277, 1988.

    PubMed  CAS  Google Scholar 

  31. Vitetta ES, Korlick KA, Miyama-Inaba M, et al.: Immunotoxins: A new approach to cancer therapy. Science 219:644–650, 1983.

    Article  PubMed  CAS  Google Scholar 

  32. Taetle R, Castagnola J, Mendelsohn J: Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies. Cancer Res 46:1759, 1986.

    PubMed  CAS  Google Scholar 

  33. Fitzgerald DJ, Willingham MC, Pastan I: Antitumor effects of an immunotoxin made with Pseudomonas extoxin in a nude mouse model of human ovarian cancer. Proc Natl Acad Sci USA 83:6627–6633, 1986.

    Article  PubMed  CAS  Google Scholar 

  34. Ceriani RL, Blank EW, Peterson JA: Experimental immunotherapy of human breast carcinomas implanted in nude mice with a mixture of monoclonal antibodies against human milk fat globule components. Cancer Res 47:532–540, 1987.

    PubMed  CAS  Google Scholar 

  35. Reisfeld RA: Immunochemical characterization of human tumor antigens. Semin Oncol 13:153–164, 1984.

    Google Scholar 

  36. Sporn MB, Roberts AB: Autocrine growth factors and cancer. Nature 313:745–747, 1985.

    Article  PubMed  CAS  Google Scholar 

  37. Cuttita F, Carney DN, Mulshine J, et al.: Bombesin-like peptides can function as autocrine growth factors in human small cell lung cancer. Nature 316:823–826, 1985.

    Article  Google Scholar 

  38. Williams LT: The sis gene and PDGF. Cancer Surv 5:223–241, 1986.

    Google Scholar 

  39. Levy R, Stratte P, Link M, et al.: Monoclonal antibodies to human lymphocytes: clinical application in therapy of leukemia. In: Kennett RH, Bechtold KB, McKearn TJ (eds): Monoclonal Antibodies and Functional Cell Lines. New York, Plenum Press, 1984, p 193.

    Google Scholar 

  40. Meeker TC, Lowder J, Maloney DG, Miller RA, Thielemans K, Warnke R, Levy R: A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 65:1349–1363, 1985.

    PubMed  CAS  Google Scholar 

  41. Cleary ML, Meeker TC, Levy S, Lee E, Trela M, Sklar J, Levy R: Clustering of extensive somatic mutations in the variable region of an immunoglobulin heavy chain gene from a human B cell lymphoma. Cell 44:97–106, 1986.

    Article  PubMed  CAS  Google Scholar 

  42. Sullivan LM, Quigley JP: An anticatalytic monoclonal antibody to avian plasminogen activator: its effect on behavior of RSV-transformed chick fibroblasts. Cell 45:905–915, 1986.

    Article  PubMed  CAS  Google Scholar 

  43. Feramisco JR, Clark R, Wong G, Arnhein N, Milley R, McCormick F: Transient reversion of ras oncogene-induced cell transformation by antibodies specific for amino acid 12 of ras protein. Nature 314:639–642, 1985.

    Article  PubMed  CAS  Google Scholar 

  44. Smith MR, DeGudicibus SJ, Stacey DW: Requirement for c-ras proteins during viral oncogene transformation. Nature 320:540–543, 1986.

    Article  PubMed  CAS  Google Scholar 

  45. Noda M, Selinger Z, Scolnick E, Bassin R: Flat revenants isolated from Kirsten sarcoma virus-transformed cells are resistant to the action of specific oncogenes. Proc Natl Acad Sci USA 80:5602–5606, 1983.

    Article  PubMed  CAS  Google Scholar 

  46. Benade L, Talbot N, Hardy K, Tagliaferri P, Card J, Noda M, Najam N, Bassin R: Ouabain sensitivity is linked to ras-transformation in human HOS cells. Biochem Biophys Res Comm 136:807–814, 1986.

    Article  PubMed  CAS  Google Scholar 

  47. Wany SY, Bassin RH, Racker E: Effect of high K+ hypertonicity and ouabain on MeAIB uptake and on growth of c-myc and v-ras transfected rat fibroblasts. Oncogene 3:53–57, 1988.

    Google Scholar 

  48. Talbot N, Tagliaferri P, Yanagihara K, Rhim JS, Bassin RH, Benade LE: A pH-dependent differential cytotoxicity of ouabain for human cells transformed by certain oncogenes. 3:23–26, 1988.

    Google Scholar 

  49. Trahey M, McCormick F: A cytoplasmic protein stimulates normal N-ras p21 GTPase but does not affect oncogenic mutants. Science 238:543–545, 1987.

    Article  Google Scholar 

  50. Fleischman LF, Chahwala SB, Cantley L: Ras-transformed cells: altered levels of phospha-tidylinositol-4, 5-biphosphate and catabolites. Science 231:407–410, 1986.

    Article  PubMed  CAS  Google Scholar 

  51. Wakelam MJO, Davies SA, Houslay MD, McKay I, Marchall CJ, Hall A: Normal p21 N-ras couples bombesin and other growth factor receptors to inositol phosphate production. Nature 323:173–176, 1986.

    Article  PubMed  CAS  Google Scholar 

  52. Wise BC, Glass DB, Jen Chou CH, Raynor RL, Katoh N, Schatzman RC, Turner RS, Kibler RF, Kuo JF: Phospholipid-sensitive Ca2+-dependent cis protein kinase from heart. II. Substrate specifity and inhibition by various agents. J Biol Chem 257:8489–8495, 1982.

    PubMed  CAS  Google Scholar 

  53. Horgan K, Cooke E, Hallett MB, Mansel RE: Inhibition of protein kinase C mediated signal transduction by tamoxifen. Biochem Pharmacol 35:4463–4465, 1986.

    Article  PubMed  CAS  Google Scholar 

  54. Hannun YA, Bell RM: Aminoacridines, potent inhibitors of protein kinase C. J Biol Chem 263:5124–5131, 1988.

    PubMed  CAS  Google Scholar 

  55. Okazaki T, Kato Y, Mochizuki T, Tashima M, Sawada H, Uchino H: Staurosporine, a novel protein kinase inhibitor, enhances HL-60 cell differentiation induced by various compounds. Exp Hematology 16:42–48, 1988.

    CAS  Google Scholar 

  56. Woll OJ, Rozengurt E: (D-Arg1,D-Phe5,D-Trp7,9,Leu11) substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro. Proc Natl Acad Sci USA 85:1859–1863, 1988.

    Article  PubMed  CAS  Google Scholar 

  57. Barbacid, M: Ras genes. Annu Rev Biochem 56:779–827, 1987.

    Article  PubMed  CAS  Google Scholar 

  58. Graziani J, Erikson E, Erikson RL: The effect of quercetin on the phosphoryl activity of the Rous sarcoma virus transforming gene product in vitro and in vivo. Eur J Biochem 135:583–589, 1983.

    Article  PubMed  CAS  Google Scholar 

  59. Akiyama T, Ishida J, Nakagawa S, Ogawara J, Watanabe SI, et al.: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262:5592–5595, 1987.

    PubMed  CAS  Google Scholar 

  60. Umezawa H, Imoto M, Sawa T, Isshiki K, Matsuda N, et al.: Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH 435-hF3. J Antibiotics 39:170–173, 1986.

    CAS  Google Scholar 

  61. Yaish P, Gazit A, Gilon C, Levitzki A: Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242:933–935, 1988.

    Article  PubMed  CAS  Google Scholar 

  62. Smith CC, Autrelion L, Reedy MP, et al.: Antiviral effect of an oligonucleotide methyl-phosphonate complementary to the splice junction of herpes simples virus type 1 immediate early pre-mRNAs 4 and 5. Proc Natl Acad Sci USA 83:2787–2791, 1986.

    Article  PubMed  CAS  Google Scholar 

  63. Zamecnik PS, Goodchild J, Taguchi Y, Sarin PS: Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonuleotides complementary to viral RNA. Proc Natl Acad Sci USA 83:4143–4146, 1986.

    Article  PubMed  CAS  Google Scholar 

  64. Holt JT, Redner RL, Nienhuis AW: An oligomer complementary to c-myc mRNA inhibits proliferation of HL60 promyelocytic cells and induces differentiation. Mol Cell Biol 8: 963–973, 1988.

    PubMed  CAS  Google Scholar 

  65. Rapp UR, Cleveland JL, Storm SM, Beck TW, Huleihel M: Transformation by raf and myc oncogenes. In: Aaronson SA, Bishop JM, Surgimura T, Terada M, Toyashimi K, Vogt PK (eds): Oncogenes and Cancer. Japan Scientific Press/VNU Scientific Press, 1987, pp 6–26.

    Google Scholar 

  66. Haffer KN, Sharpee RL, Beckenhauer WH: Feline leukemia vaccine protection against viral latency. Vaccine 5:237–240, 1987.

    Article  Google Scholar 

  67. Pfister H: Human papilloma virus and genital cancer. Adv Cancer Res 48:113–147, 1987.

    Article  PubMed  CAS  Google Scholar 

  68. Koeffler HP: Induction of differentiation of human acute myelogenous leukemia cells: Therapeutic implications. Blood 62:709–721, 1983.

    PubMed  CAS  Google Scholar 

  69. Gewirtz AM, Calabretta B: A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. Science 242:1303–1306, 1988.

    Article  PubMed  CAS  Google Scholar 

  70. Jaskalski O, DeRiel JK, Mercer WE, Calabretta B, Baserga R: Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA cyclin. Science 240:1544–1546, 1988.

    Article  Google Scholar 

  71. van der Krol AR, Mol JNM, Stuitje AR: Modulation of eukaryotic gene expression by complementary RNA and DNA sequences. Biotechniques 6:958–976, 1988.

    PubMed  Google Scholar 

  72. Miller PS, Ts’o POP: A new approach to chemotherapy based on molecular biology and nucleic acid chemistry: Matagen (masking tape for gene expression). Anti-Cancer Drug Design 2:117–128, 1987.

    PubMed  CAS  Google Scholar 

Download references